Spruce Biosciences to Participate in May 2024 Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May.

• The JMP Securities Life Sciences Conference
  Date: May 13-14, 2024
  Format: Fireside chat (May 14, 2024 at 10:30 a.m. ET) and 1x1 meetings

• 2024 RBC Capital Markets Global Healthcare Conference
  Date: May 14-15, 2024
  Format: Fireside chat (May 15, 2024 at 8:30 a.m. ET) and 1x1 meetings

The live webcast for each conference presentation can be accessed on the events section of the company’s investor relations website and will be available for replay after the conclusion of the live presentations for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501727100/en/